Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.

Liu Y, Mo CC, Hartley-Brown MA, Sperling AS, Midha S, Yee AJ, Bianchi G, Piper C, Tattersall A, Nadeem O, Laubach JP, Richardson PG.

Open source

DOI: 10.1080/17474086.2024.2382897
Published: 2024-07-27
Container: Expert Rev Hematol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/17474086.2024.2382897,
  title = {Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.},
  author = {Liu Y and  Mo CC and  Hartley-Brown MA and  Sperling AS and  Midha S and  Yee AJ and  Bianchi G and  Piper C and  Tattersall A and  Nadeem O and  Laubach JP and  Richardson PG.},
  year = {2024},
  journal = {Expert Rev Hematol},
  doi = {10.1080/17474086.2024.2382897},
  url = {https://doi.org/10.1080/17474086.2024.2382897}
}

RIS

TY  - JOUR
TI  - Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
AU  - Liu Y
AU  -  Mo CC
AU  -  Hartley-Brown MA
AU  -  Sperling AS
AU  -  Midha S
AU  -  Yee AJ
AU  -  Bianchi G
AU  -  Piper C
AU  -  Tattersall A
AU  -  Nadeem O
AU  -  Laubach JP
AU  -  Richardson PG.
PY  - 2024
JO  - Expert Rev Hematol
DO  - 10.1080/17474086.2024.2382897
UR  - https://doi.org/10.1080/17474086.2024.2382897
ER  -

APA

Y, L., CC, M., MA, H., AS, S., S, M., AJ, Y., G, B., C, P., A, T., O, N., JP, L., & PG., R. (2024). Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.. Expert Rev Hematol. https://doi.org/10.1080/17474086.2024.2382897

Source records

europe-pmc · retrieved 2026-09-27T03:13:51.861Z